Clinical Trials for Cancer Treatment

Study Title:

EMBER-4: A Randomized, Open-Label, Phase 3 Study of
Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who
have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+,
HER2- Early Breast Cancer with an Increased Risk of Recurrence

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of the study is to see how safe an investigational drug (imlunestrant) is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence as compared to endocrine therapy.

Upstate Institutional Review Board (IRB) Number:

2020613

Study/Protocol ID:

2020613

Study Phase:

phase 3

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

Who is eligible?

Individuals who have received definitive locoregional therapy, received 2 to 5 years of standard adjuvant ET without disease recurrence, and must have an increased risk of recurrence based on clin-path features at diagnosis.

What is involved if I participate?

How long is the study?
10 years
Is transportation provided or reimbursed?
No
Is parking provided or reimbursed?
No
What tests and procedures are involved?
mammogram, CT Thorax, Abdomen, and Pelvis